Clinical Edge Journal Scan

Risk factors for postoperative arm lymphedema in breast cancer


 

Key clinical point: Several preoperative and postoperative factors predict the risk for arm lymphedema in patients who undergo breast cancer (BC) surgery.

Major finding: Young age (<60 years; P < .001), high body mass index (P < .001), advanced preoperative T and N classifications (P ≤ .01), total mastectomy (P < .001), axillary dissection (P < .001), and collagen disease (P = .024) were the preoperative risk factors for lymphedema. Postoperative bleeding (P = .017), chemotherapy (P < .001), and radiotherapy (P < .001) were among the postoperative risk factors for lymphedema.

Study details: Findings are from a nationwide retrospective cohort study including 84,022 women who underwent BC surgery, of which 1547 patients received treatments for lymphedema.

Disclosures: This work was supported by the Ministry of Health, Labour and Welfare, Japan, and other sources. N Michihata declared serving as an employee at The University of Tokyo.

Source: Konishi T et al. Risk factors for arm lymphedema following breast cancer surgery: A Japanese nationwide database study of 84,022 patients. Breast Cancer. 2022 (Aug 23). Doi: 10.1007/s12282-022-01395-5.

Recommended Reading

Time to cancer diagnoses in U.S. averages 5 months
MDedge Hematology and Oncology
De-escalation of locoregional radiotherapy after primary chemotherapy appears safe in cT1-2N1 BC
MDedge Hematology and Oncology
Sacituzumab govitecan bests chemotherapy in HR+/HER2− advanced BC
MDedge Hematology and Oncology
Early TNBC: Durvalumab+NACT improves survival despite modest pCR increase
MDedge Hematology and Oncology
Neratinib alone or in combination with capecitabine beneficial for advanced HER2+ BC
MDedge Hematology and Oncology
Reassuring survival outcomes with trastuzumab+lapatinib in small and node-negative HER2+ BC
MDedge Hematology and Oncology
Risk for brain metastasis highest with ERBB2+ and triple-negative metastatic BC
MDedge Hematology and Oncology
ER+/HER2+ BC: HER2-enriched subtype predicts poor response to AI therapy
MDedge Hematology and Oncology
Fertility preservation safe in young women with BC
MDedge Hematology and Oncology
LetCOH as effective as cCOH for fertility preservation in nonmetastatic BC
MDedge Hematology and Oncology